Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Silly Analogy

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on May 21, 2021 1:48pm

141 Views

Post# 33248706

RE:Silly Analogy

Trigger event New ceo I will double my holding

GameChangerBet wrote: Remember as a child playing with those pull back toy cars?
The more you would pull back the car and wind it up the stronger the acceleration and speed would be once released.
I feel that ATE will have a similar outcome.
The stock needs a trigger event for the release to happen.

Just for fun:
https://www.youtube.com/watch?v=l52dblX2-tU